Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Basis for Resistance to Imatinib in 16 BCR-ABL Mutants as Determined Using Molecular Dynamics

Author(s): Tai-Sung Lee, Steven J. Potts and Maher Albitar

Volume 4, Issue 2, 2009

Page: [164 - 173] Pages: 10

DOI: 10.2174/157489209788452867

Price: $65

Abstract

Large-scale (∼36,000 atoms) long-time (30 ns each) molecular dynamics (MD) simulations on the complex of imatinib and 16 common mutants of the ABL tyrosine kinase domain have been performed to study the imatinib resistance mechanisms at the atomic level. MD simulations show that long time computational simulations could offer insight information that static models, simple homology modeling methods, or short-time simulations cannot provide for the BCR-ABL imatinib resistance problem. Three possible types of mutational effects from those mutants are found: the direct effect on the contact interaction with imatinib (e.g. some P-loop mutations), the effect on the conformation of a remote region contacting with imatinib (e.g. T315I), and the effect on interaction between two regions within the BCR-ABL domain (e.g. H396P). Insights of possible imatinib resistance mechanisms, not consistent with current consensus, are revealed from various analyses and our findings suggest that drugs with different binding modes may be necessary to overcome the drug resistance due to T315I and other mutations. The relevant patents are discussed.

Keywords: BCR-ABL, imatinib resistance, molecular dynamics simulation, MD simulation


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy